Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 3/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.34 |
| ▸ | ACP1 | P24666 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4898823 | 0.95 | TNK2 (0.43) | TNK2HSD11B1MEN1KMT2ADHFR | |
| SCHEMBL16055037 | 0.92 | HSD11B1 (0.41) | TNK2HSD11B1MEN1KMT2ADHFR | |
| SCHEMBL17307389 | 0.91 | TNK2 (0.36) | TNK2HSD11B1MEN1KMT2ADHFR | |
| SCHEMBL15512365 | 0.91 | TNK2 (0.36) | TNK2HSD11B1MEN1KMT2ADHFR | |
| SCHEMBL3500438 | 0.91 | TNK2 (0.44) | TNK2HSD11B1MEN1KMT2ADHFR | |
| SCHEMBL14184919 | 0.89 | NPY1R (0.38) | TNK2HSD11B1MEN1KMT2ADHFR | |
| SCHEMBL17307392 | 0.86 | MEN1 (0.35) | TNK2HSD11B1MEN1KMT2ADHFR | |
| SCHEMBL6824651 | 0.85 | DHFR (0.42) | TNK2HSD11B1MEN1KMT2ADHFR | |
| SCHEMBL6825236 | 0.85 | DHFR (0.42) | TNK2HSD11B1MEN1KMT2ADHFR | |
| SCHEMBL14852899 | 0.82 | TNK2 (0.46) | TNK2HSD11B1MEN1KMT2ADHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 224 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2000066593-A2 | NOVEL SPIROCYCLIC COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE FOR TREATING HYPERPROLIFERATIVE DISEASES | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-11-09 | — | — | WO | claimed |
| CN-121293478-A | Synthesis method of cyclic polyol and preparation method of polyurethane elastomer material | 江苏新澄瑞材料科技有限公司 | 2026-01-09 | — | — | CN | disclosed |
| CN-119684303-A | Heterocyclic compound of difunctional degradable androgen receptor and application thereof | 上海超阳药业有限公司 | 2025-03-25 | — | — | CN | disclosed |
| CN-114207082-B | Liquid crystal mixture and liquid crystal display | 默克专利股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-118574821-A | Compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2024-08-30 | — | — | CN | disclosed |
| EP-3601388-B1 | BIS-BIPHENYL-PHENOXY CATALYSTS FOR OLEFIN POLYMERIZATION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2024-08-07 | — | — | EP | disclosed |
| CN-117736231-A | Process method for synthesizing 4-hydroxycyclohexene-1-boric acid pinacol ester | 大连双硼医药化工有限公司 | 2024-03-22 | — | — | CN | disclosed |
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-11-30 | — | — | US | disclosed |
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-11-30 | — | — | US | disclosed |
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-11-30 | — | — | US | disclosed |
| EP-0221368-A2 | Substituted 1,1,2-triphenyl-1-butene | ASTA Pharma Aktiengesellschaft (DE) | 1987-05-13 | — | — | EP | disclosed |
| US-4623660-A | ANTIESTROGENS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-11-18 | — | — | US | disclosed |
| EP-0104387-A1 | 11-Beta-aryl-17-alpha-alkynyl-17-beta-hydroxy-4,9(10)-estradien-3-one derivatives, their preparation and pharmaceutical compositions containing them | SCHERING AKTIENGESELLSCHAFT (DE) | 1984-04-04 | — | — | EP | disclosed |
| EP-0002097-B1 | TRIPHENYLALKENE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1981-08-05 | — | — | EP | disclosed |
| US-4206234-A | Triphenylbut-1-ene derivatives and pharmaceutical compositions and uses thereof | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1980-06-03 | — | — | US | disclosed |
| US-4198435-A | Pharmaceutical compositions | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1980-04-15 | — | — | US | disclosed |
| EP-0002097-A1 | Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1979-05-30 | — | — | EP | disclosed |
| US-4070541-A | Diarylmethylenes | ORTHO PHARMACEUTICAL CORPORATION (US) | 1978-01-24 | — | — | US | disclosed |
| US-4054667-A | METAMORPHOSIS INHIBITION | STAUFFER CHEMICAL COMPANY (US) | 1977-10-18 | — | — | US | disclosed |
| US-3936493-A | Diarylmethylenes | ORTHO PHARMACEUTICAL CORPORATION (US) | 1976-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NTPCR | TNK2 2908/4885HSD11B1 893/4885MEN1 3871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.